Immediate adverse impact of DPCO 2013, on both sales and margins, will be quite significant to OPPI member companies. However, a change from cost-based to market-based pricing methodology is expected to have transparency and be directionally more prudent for the pharma industry on a longer term perspective.
– Tapan Ray, Director General, Organisation of Pharmaceutical Producers Of India (OPPI)
